SG10201804024VA - Formulations of azaindole compounds - Google Patents

Formulations of azaindole compounds

Info

Publication number
SG10201804024VA
SG10201804024VA SG10201804024VA SG10201804024VA SG10201804024VA SG 10201804024V A SG10201804024V A SG 10201804024VA SG 10201804024V A SG10201804024V A SG 10201804024VA SG 10201804024V A SG10201804024V A SG 10201804024VA SG 10201804024V A SG10201804024V A SG 10201804024VA
Authority
SG
Singapore
Prior art keywords
compound
pharmaceutical composition
formulations
hcl salt
composition comprises
Prior art date
Application number
SG10201804024VA
Other languages
English (en)
Inventor
Eric Simone
Tapan Sanghvi
Alamelu Banda
Katherine Stavropoulos
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201804024V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SG10201804024VA publication Critical patent/SG10201804024VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG10201804024VA 2013-11-13 2014-11-12 Formulations of azaindole compounds SG10201804024VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361903840P 2013-11-13 2013-11-13

Publications (1)

Publication Number Publication Date
SG10201804024VA true SG10201804024VA (en) 2018-07-30

Family

ID=52001095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201804024VA SG10201804024VA (en) 2013-11-13 2014-11-12 Formulations of azaindole compounds

Country Status (13)

Country Link
US (3) US20160250213A1 (fr)
EP (1) EP3068434A1 (fr)
JP (2) JP2016537347A (fr)
KR (1) KR20160084465A (fr)
CN (1) CN105848683A (fr)
AU (1) AU2014348762A1 (fr)
CA (1) CA2930105A1 (fr)
CL (1) CL2016001111A1 (fr)
IL (2) IL245587A0 (fr)
MX (1) MX2016006197A (fr)
RU (1) RU2685730C1 (fr)
SG (1) SG10201804024VA (fr)
WO (1) WO2015073491A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031048T2 (en) 2009-06-17 2017-06-28 Vertex Pharma Influenza virus replication inhibitors
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
CA2930103A1 (fr) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Inhibiteurs de la replication des virus de la grippe
CN105849105B (zh) 2013-11-13 2018-02-13 沃泰克斯药物股份有限公司 制备流感病毒复制抑制剂的方法
WO2016183116A1 (fr) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Procédés de préparation d'inhibiteurs de réplication des virus de la grippe
EP3294735B8 (fr) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibiteurs de la réplication des virus de la grippe
KR20180088466A (ko) 2015-12-09 2018-08-03 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제 저해제, 활용 방법 및 그 용도
US10501444B2 (en) 2016-08-16 2019-12-10 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
JP7034162B2 (ja) * 2016-12-15 2022-03-11 サンシャイン・レイク・ファーマ・カンパニー・リミテッド インフルエンザウイルス複製の阻害剤及びその使用
WO2018127096A1 (fr) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibiteurs de réplication du virus de la grippe et utilisations associées
WO2018137670A1 (fr) * 2017-01-24 2018-08-02 苏州科睿思制药有限公司 Forme cristalline du médicament inhibiteur de protéine virale (vx-287), et son procédé de préparation et d'utilisation
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018191475A1 (fr) * 2017-04-12 2018-10-18 Vertex Pharmaceuticals Incorporated Polythérapies pour le traitement d'infection par le virus de la grippe
JP7175966B2 (ja) * 2017-08-31 2022-11-21 ノバルティス アーゲー 顆粒剤を調製する方法
EP3774794A1 (fr) * 2018-04-06 2021-02-17 Janssen Pharmaceuticals, Inc. Procédé de cristallisation réactive isotherme pour la préparation d'une forme cristalline d'hémihydrate de chlorhydrate de pimodivir
WO2020058745A1 (fr) * 2018-09-18 2020-03-26 Shionogi & Co., Ltd. Traitement de la grippe à l'aide de dérivés de pyridone polycycliques substitués et leurs promédicaments
MX2021005582A (es) * 2018-11-13 2021-06-30 Cocrystal Pharma Inc Formulaciones de terapias contra la gripe.
KR20200106607A (ko) * 2019-03-05 2020-09-15 주식회사 코아팜바이오 오셀타미비르 함유 의약 조성물
US20200397784A1 (en) * 2019-06-20 2020-12-24 Janssen Pharmaceuticals, Inc. Formulations of azaindole compounds
CN112578034B (zh) * 2020-11-04 2022-02-11 广东众生睿创生物科技有限公司 一种手性胺小分子及其盐的质量控制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681815A (en) * 1993-06-28 1997-10-28 Sophie Chen Antiviral and antitumor agents
LT2486942T (lt) * 2004-11-24 2019-01-25 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną ir jų panaudojimo būdai
US20120093738A1 (en) * 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
HUE031048T2 (en) * 2009-06-17 2017-06-28 Vertex Pharma Influenza virus replication inhibitors

Also Published As

Publication number Publication date
RU2016122609A (ru) 2017-12-18
WO2015073491A1 (fr) 2015-05-21
RU2685730C1 (ru) 2019-04-23
IL245587A0 (en) 2016-06-30
KR20160084465A (ko) 2016-07-13
CL2016001111A1 (es) 2017-06-09
JP2016537347A (ja) 2016-12-01
IL278214A (en) 2020-11-30
MX2016006197A (es) 2016-08-08
CA2930105A1 (fr) 2015-05-21
AU2014348762A1 (en) 2016-05-26
US20180318301A1 (en) 2018-11-08
EP3068434A1 (fr) 2016-09-21
JP2021191796A (ja) 2021-12-16
US20160250213A1 (en) 2016-09-01
US20210008072A1 (en) 2021-01-14
CN105848683A (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
SG10201804024VA (en) Formulations of azaindole compounds
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
MX354102B (es) Derivados de bencimidazol-prolina.
BR112015023705A8 (pt) compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX2013001677A (es) Formulaciones estables de linaclotida.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MX2013012289A (es) Triazolopiridinas.
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
NZ714558A (en) Formulation comprising a hypolipidemic agent
MX2014013851A (es) Composiciones farmaceuticas topicas que comprenden terbinafina y urea.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EA201201109A1 (ru) Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его
PH12015502632A1 (en) Cxcr7 receptor modulators
HRP20191322T1 (hr) Antitumorska kombinacija koja sadži kabazitaksel i cisplatin
EA201600394A1 (ru) Трициклические соединения пиперидина
GEP20135997B (en) Tricyclic indazole compound, method of their preparation and pharmaceutical composition containing thereof
EA201490573A1 (ru) Соединение бензотиазолона
HRP20151340T1 (hr) Derivati tieno[2,3-d] pirimidina i njihova primjena u lijeäśenju aritmije
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
MX362905B (es) Tratamiento de combinacion.
WO2014006635A3 (fr) Compositions orales solides de silodosine
HRP20231448T1 (hr) Primjena delgocitiniba za liječenje kroničnog ekcema ruku